Search hospitals

>

Illinois

>

Effingham

Crossroads Cancer Center

Claim this profile

Effingham, Illinois 62401

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Breast cancer

357 reported clinical trials

3 medical researchers

Photo of Crossroads Cancer Center in EffinghamPhoto of Crossroads Cancer Center in EffinghamPhoto of Crossroads Cancer Center in Effingham

Summary

Crossroads Cancer Center is a medical facility located in Effingham, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. Crossroads Cancer Center is involved with conducting 357 clinical trials across 447 conditions. There are 3 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, and Harold Yoon, MD.

Area of expertise

1

Lung Cancer

Global Leader

Crossroads Cancer Center has run 68 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Breast Cancer

Global Leader

Crossroads Cancer Center has run 61 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Crossroads Cancer Center

Lung Cancer

Prostate Cancer

Breast Cancer

Breast cancer

Cancer

Kidney Cancer

Pancreatic Cancer

Ovarian Cancer

Multiple Myeloma

Esophageal cancer

Image of trial facility.

Radiotherapy

for Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Crossroads Cancer Center?

Where is Crossroads Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Crossroads Cancer Center accept?

What awards or recognition has Crossroads Cancer Center received?